Detection of germ cell tumor cells in apheresis products using polymerase chain reaction

Clinical Cancer Research

Volumn 4, Issue 1, 1998, Pages 93-98

  Fan, Yi ^a   Einhorn, Lawrence ^a   Saxman, Scott ^a   Katz, Barry ^a   Abonour, Rafat ^a   Cornetta, Kenneth ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT;

APHERESIS; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CLINICAL ARTICLE; FEMALE; GERM CELL TUMOR; HUMAN; LYMPHOMA; MALE; METASTASIS; PERIPHERAL BLOOD STEM CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION;

BLOOD COMPONENT REMOVAL; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; GERMINOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASM CIRCULATING CELLS; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RNA, MESSENGER;

EID: 0031881601     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Einhorn, L. Treatment of testicular cancer: a new and improved model. J. Clin. Oncol., 8: 1777-1781, 1990.
2. Bosl, G., Geller, N., Cirrincione, C., Vogelzang, N. J., Kennedy, B. J., Whitmore, W. F., Vugrin, D., Scher, H., Nisselbaum, J., and Golbey, R. B. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res., 43: 3403-3407, 1983.
3. Birch, R., Wiliams, S., Cone, A., Einhorn, L., Roark, P., Turner, S., and Greco, F. A. Prognostic factors for favorable outcome in disseminated germ cell tumors. J. Clin. Oncol., 4: 400-407, 1986.
4. Levi, J., Raghavan, D., Harvey, V., Thompson, D., Sandeman, T., Gill, G., Stuart-Harris, R., Snyder, R., Byrne, M., Kerestes, Z., and Margrie, S. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. J. Clin. Oncol., 11: 1300-1305, 1993.
5. Loehrer, P., Johnson, D., Elson, P., Einhorn, L., and Trump, D. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol., 13: 470-476, 1995.
6. Einhorn, L. H., Williams, S. D., Loehrer, P. J., Birch, R., Drasga, R., Omura, G., and Greco, F. A. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J. Clin. Oncol., 7: 387-391, 1989.
7. Bajorin, D., Sarosdy, M., Pfister, D., Pfister, D. G., Mazumdar, M., Motzer, R. J., Scher, H. I., Geller, N. L., Fair, W. R., Herr, H., Sogani, P., Sheinfeld, J., Russo, P., Vlamis, V., Carey, R., Vogelzang, N. J., Crawford, E. D., and Bosl, G. J. A randomized trial of etoposide + cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multi-institutional study. J. Clin. Oncol., 11: 598-606, 1993.
8. Nichols, C., Williams, S., Loehrer, P., Greco, F. A., Crawford, E. D., Weetlaufer, J., Miller, M. E., Bartolucci, A., Schacter, L., and Einhorn, L. H. Randomized study of cisplatin dose intensity in advanced germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J. Clin. Oncol., 9: 1163-1172, 1991.
9. Nichols, C. R., Loehrer, P. J., Einhorn, L. H., Propert, K., Vogelzang, N. J., Crawford, E. D., Sarosdy, M., and Trump, D. Phase III study of cisplatin, etoposide, and bleomycin (PVP-16B) or etoposide, ifosfamide, and cisplatin (VIP) in advanced-stage germ cell tumors: an Intergroup trial. Proc. Am. Soc. Clin. Oncol., 14: 239, 1995.
10. Kaye, S. B., Mead, G. M., Fossa, S., Cullen, M., De Wit, R., Bodrogi, I., van Groeningen, C., Sylvester, R., Stenning, S., Vermeylen, K., Lallemand, E., and de Mulder, P. An MRC/EORTC randomized trial in poor-prognosis metastatic teratoma, comparing BEP to BOP-VIP. Proc. Am. Soc. Clin. Oncol., 14: 246, 1995.
11. Droz, J. P., Pico, J. L., Ghosn, M., Kramar, A., Rey, A., Ostronoff, M., and Baume, D. A Phase II trial of early intensive chemotherapy with autologous bone marrow transplantation in the treatment of poor-prognosis nonseminomatous germ cell tumors. Bull. Cancer (Paris), 79: 497-507, 1992.
12. Nichols, C. R., Tricot, G., Williams, S. D., van Besien, K., Loehrer, P. J., Roth, B. J., Akard, L., Hoffman, R., Goulet, R., Wolff, S. N., and Einhorn, L. Dose-intensive chemotherapy in refractory germ cell cancer: a Phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J. Clin. Oncol., 7: 932-939, 1989.
13. Motzer, R. J., and Bosl, G. J. High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions. J. Natl. Cancer Inst., 84: 1703-1709, 1992.
14. Broun, E. R., Nichols, C. R., Kneebone, P., Williams, S. D., Loehrer, P. J., Einhorn, L. H., and Tricot, G. J. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann. Intern. Med., 117: 124-128, 1992.
15. Beyer, J., Kingreen, D., Krause, M., Schleicher, J., Schwaner, I., Schwella, N., Huhn, D., and Siegert, W. Long-term survival of patents with recurrent or refractory germ cell tumors after high-dose chemotherapy. Cancer (Phila.), 79: 161-168, 1997.
16. Broun, E. R., Nichols, C. R., Gize, G., Cornetta, K., Hromas, R., Schacht, B., and Einhorn, L. H. Tandem high-dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. Cancer (Phila.), 79: 1605-1610, 1997.
17. Adkins, D., Encarnacion, C., Salzman, D., Boldt, D., Freytes, C., Von Hoff, D. D., and LeMaistre, C. F. Durable complete remission in a patient with refractory mediastinal nonseminomatous germ cell tumor after tandem high-dose chemotherapy and autologous bone marrow transplantation. Bone Marrow Transplant., 12: 541-546, 1993.
18. Brenner, M. K., Rill, D. R., Moen, R. C., Krance, R. A., Mirro, J., Jr., Anderson, W. F., and Ihle, J. N. Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet, 341: 85-86, 1993.
19. Deisseroth, A. B., Zu, Z., Claxton, D., Hanania, E. G., Fu, S., and Ellerson, D. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood, 83: 3068-3074, 1994.
20. Gribben, J. G., Freedman, A. S., Neuberg, D., Roy, D. C., Blake, K. W., Woo, S. D., Grossbard, M. L., Rabinowe, S. N., Coral, F., Freedman, G. J., Ritz, J., and Nadler, L. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N. Engl. J. Med., 325: 1525-1533, 1991.
21. Ross, A. A., Cooper, B. W., Lazarus, H. M., Mackay, W., Moss, T. J., Ciobanu, N., Tallman, M. S., Kennedy, M. J., Davidson, N. E., Sweet, D., Winter, C., Akard, L., Jansen, J., Copelan, E., Meagher, R. C., Herzig, R. H., Klumpp, T. R., Kahn, D. G., and Warner, N. E. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood, 82: 2605-2610, 1993.
22. Brugger, W., Bross, K. J., Glatt, M. G., Weber, F., Mertelsmann, R., and Kanz, L. Mobilzation of tumor cells and hematoietic progenitor cells into peripheral blood of patients with solid tumors. Blood, 83: 636-640, 1994.
23. Fields, K. K., Elfenbein, G. J., Trudeau, W. L., Perkins, J. B., Janssen, W. E., and Moscinski, L. C. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J. Clin. Oncol., 14: 1868-1876, 1997.
24. Dunbar, C. E., Cottler-Fox, M., O'Shaughnessy, J. A., Doren, S., Carter, C., Berenson, R., Brown, S., Moen, R. C., Greenblatt, J., Stewart, F. M., Leitman, S. F., Wilson, W. H., Cowan, K., Young, N. S., and Nienhuis, A. W. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood, 85: 3048-3057, 1995.
25. Berger, P., Kranewitter, W., Madersbacher, S., Gerth, R., Geley, S., and Dirnhofer, S. Eutopic production of human chorionic gonadotropin β (hCGβ) and luteinizing hormone β (hLHβ) in the human testis. FEBS Lett., 343: 229-233, 1994.
26. Bo, M., and Boime, I. Identification of the transcriptionally active genes of the chorionic gonadotropin β gene cluster in vivo. J. Biol. Chem., 267: 3179-3184, 1992.
27. Hosmer, D. W., and Lemeshow, S. Applied Logistic Regression. Wiley Series in Probability and Mathematical Statistics. New York: John Wiley & Sons, Inc., 1989.
28. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognositic factor-based staging system for metastatic germ cell cancer. J. Clin. Oncol., 15: 594-603, 1997.
29. Miyamura, K., Barrett, A. J., Kodera, Y., and Saito, H. Minimal residual disease after bone marrow transplantation for chronic myelogenous leukemia and implications for graft-versus-leukemia effect: a review of recent results. Bone Marrow Transplant., 14: 201-209, 1994.
30. Neale, G. A. M., Menarguez, J., Kitchingman, G. R., Fitzgerald, T. J., Koehler, M., Mirro, J., and Goorha, R. M. Detection of minimal residual disease in T-cell acute lymphoblastic leukemia using polymerase chain reaction predicts impending relapse. Blood. 78: 739-747, 1991.
31. Gehly, G. B., Bryant, E. M., Lee, A. M., Kidd, P. G., and Thomas, E. D. Chimeric BCR-abl messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood, 78: 458-465, 1991.
32. Yamada, M., Wasserman, R., Lange, B., Reichard, B. A., Womer, R. B., and Rovera, G. Minimal residual disease in childhood B-lineage lymphoblastic leukemia. Persistence of leukemic cells during the first 18 months of treatment. N. Engl. J. Med., 323: 448-455, 1990.
33. Roberts, W. M., Estrov, Z., Ouspenskaia, M. V., Johnston, D. A., McClain, K. L., and Zipf, T. F. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N. Engl. J. Med., 336: 317-323, 1997.
34. Cooper, M. A., and Einhorn, L. H. Maintenance chemotherapy with daily oral VP-16 following salvage therapy in patients with germ cell tumors. J Clin. Oncol., 13: 1167-1169, 1995.